Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus

Journal of Clinical Pharmacology

Volumn 42, Issue 2, 2002, Pages 222-228

  Kovarik, John M ^a   Hartmann, Stefan ^a   Hubert, Martine ^b   Berthier, Stephane ^a   Schneider, Werner ^a   Rosenkranz, Bernd ^c,d   Rordorf, Christiane ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Rueil Malmaison ^*  (France)

^c PAREXEL INTERNATIONAL   (United States)

^d ClinicalResearch AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FLATULENCE; HEADACHE; HUMAN; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PLASMA; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PRAVASTATIN; PYRROLES; SIROLIMUS;

EID: 0036157484     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700222011148     Document Type: Article

References (15)

1. Hyperlipidemia in solid organ transplantation
2. Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient
3. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
4. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine
5. The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients
6. Drug interaction-induced rhabdomyolysis
7. Clinically significant drug interactions with cyclosporine: An update
8. RAD in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection
9. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
10. A worldwide, phase 3, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
11. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
12. Development of a high-performance liquid chromatography mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin and para-hydroxy atorvastatin in human, dog and rat plasma
13. Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications
14. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine
15. Everolimus pharmacokinetics in de novo renal transplant patients: Dose-proportional, stable exposure over 6 months